<DOC>
	<DOCNO>NCT02358356</DOCNO>
	<brief_summary>Two parallel phase II randomize open label trial Lutetium-177 Octreotate ( 177Lu‐Octreotate ) peptide receptor radionuclide therapy ( PRRT ) capecitabine ( CAP ) /temozolomide ( TEM ) chemotherapy ( chemo ) : ( ) versus CAPTEM alone treatment low intermediate grade pancreatic neuroendocrine tumour ( pNETs ) ; ( ii ) versus PRRT alone treatment low intermediate grade mid gut neuroendocrine tumour ( mNETs ) .</brief_summary>
	<brief_title>Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study</brief_title>
	<detailed_description>PROTOCOL SYNOPSIS Background Neuroendocrine tumour ( NETs ) heterogeneous group malignancy arise site gastrointestinal tract , know ability express somatostatin receptor . Originally call carcinoid tumour , tumours rise incidence . In patient incurable disease , several systemic option demonstrate activity compare prospective , randomise control trial ( RCTs ) . 177Lu-Octreotate peptide receptor radionuclide therapy ( PRRT ) CAPTEM show promising activity initial single arm trial . Prospective RCTs need build early trial determine optimal role therapy clinical practice . CONTROL NETs parallel group phase II randomise open label trial Lutetium-177 Octreotate ( 177Lu‐Octreotate ( Lutate ) ) peptide receptor radionuclide therapy ( PRRT ) capecitabine ( CAP ) /temozolomide ( TEM ) chemotherapy ( chemotherapy ) : ( ) versus CAPTEM alone treatment low intermediate grade pancreatic neuroendocrine tumour ( pNETs ) ; ( ii ) versus PRRT alone treatment low intermediate grade midgut neuroendocrine tumour ( mNETs ) . General aim ) To determine relative activity CAPTEM/PRRT biopsy-proven , low intermediate grade , unresectable , metastatic 68Ga-octreotate PET-avid NETs follow parallel phase II study : Group A : pNETs Group B : mNETs . ii ) To inform future comparative phase III RCTs determine optimal therapy pNETs mNETs . Design Two parallel non-comparative group randomise , control , multi-centre phase II , 2 arm open‐label control trial 2:1 allocation ( experimental : control ) 1 . Study A : pNETs : PRRT/CAPTEM vs. CAPTEM ( control ) 2 . Study B : mNETs : PRRT/CAPTEM vs. PRRT ( control ) Randomisation perform use method minimisation . Patients stratify : - Previous systemic therapy regimen ( 0,1 v 2 ) - WHO tumour grade : Low Grade - G1 ( Ki67 &lt; 3 % ( mitotic count &lt; 2 ) ) vs. Intermediate Grade - G2 ( Ki67 3-20 % ( mitotic count 2-20 ) ) - visceral vs. visceral bone metastases - Treating institution Population The target population study consent adult patient advance , unresectable low intermediate grade ( Ki-67 &lt; 20 % ) midgut neuroendocrine tumour ( mNETs ) pancreatic neuroendocrine tumour ( pNETs ) , receive ≤ 2 prior systemic therapy advance unresectable disease ( include long act somatostatin analogue ) . Assessments - Patients assessed treatment cycle toxicity - CT include 3 phase contrast CT liver undertaken baseline , every 2 month ( pNET ) every 4 month ( pNET ) radiologic progression RECIST v1.1 . - 68Ga-DOTATATE PET CT Scan undertaken baseline , every 4 month radiologic progression RECIST v1.1 . - 18F-FDG PET Scan may perform discretion treat clinician baseline , every 2 month radiologic progression RECIST v1.1 ) G2 NETS . - 24-h whole-body planar gamma image undertaken day administration PRRT ( every 2 month ) . - Serum biomarkers undertake every 4 month disease progression . - Quality life assessment undertaken every 2 month disease progression use QLC C30 QLQ-GINET21 . - Health utility evaluate EQ-5D-5L every 2 month completion study follow . Statistical consideration Both study base Simon 's two-stage design randomise use 2:1 randomisation ( Experimental : Control ) . A mix approximately 30 % G1 patient 70 % G2 patient expect . Study A , pNETs ( n=90 ) 80 % power 95 % confidence interval exclude 12 month PFS 60 % favour interesting rate 77 % experimental arm . For Study B , mNETs ( n=75 ) , PFS 24 month control arm expect 52 % . Thus study B 80 % power 95 % confidence interval demonstrate PFS rate 24 month 70 % experimental arm , result would warrant investigation . A total sample size 165 patient two study accrue 2 year . Patients follow minimum 2 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Adults ≥18 year old histologically proven , moderate well‐differentiated G1/2 pancreatic midgut NETs Ki‐67 &lt; 20 % ; The presence somatostatin receptor avidity suitable PRRT demonstrate 68Ga‐octreotate PET scan ; Progressive advanced/metastatic disease progress ≤ 2 prior systemic therapy ; Unresectable disease , determine appropriately specialize surgeon deem suitable liver direct therapy liver site disease ; ECOG performance status 0‐2 ; Ability swallow oral medication ; Adequate renal function ( measure creatinine clearance &gt; 50 ml/min DTPA 51CREDTA ) , bone marrow function ( Hb &gt; 9 g/d/L , ANC &gt; 1.5 x109L , platelet &gt; 100 x 10/L ) ; Adequate liver function ( serum total bilirubin ≤ 1.5 x ULN , Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) , Alkaline phosphatase ( ALP ) ≤ 2.5 x ULN ( ≤ 5 x ULN patient liver metastasis ) ) . INR ≤ 1.5 ( stable dose LMW heparin &gt; 2 week time enrolment . ) ; Life expectancy least 9 month ; Study treatment plan able start within 28 day randomisation ; ) Willing able comply study requirement , include treatment , time and/or nature require assessment ; Signed , write informed consent . Primary NETs small bowel ( midgut ) pancreatic NETs ; Cytotoxic chemotherapy , target therapy , biotherapy within last four week ; Prior intrahepatic 90Y microspheres , SIRSpheres past six month ; Prior Peptide Receptor Radionuclide Therapy ; Major surgery/surgical therapy cause within one month ; Surgical therapy locoregional metastasis within last three month prior randomisation ; Uncontrolled metastatic disease central nervous system . To eligible , CNS metastases treat surgery and/or radiotherapy patient receive stable dose steroid least 2 week prior randomisation , deterioration neurological symptom time ; Poorly control concurrent medical illness . E.g . unstable diabetes ( Note : optimal glycaemic control achieve start trial therapy ) ; Symptomatic NYHA class III IV congestive cardiac failure , myocardial infarction within 6 month start study , serious uncontrolled cardiac arrhythmia , unstable angina , clinically significant cardiac disease ; History malignancy within 5 year except treated curative intent AND current evidence disease AND consider risk future recurrence Patients past history adequately treat carcinomainsitu , basal cell carcinoma skin , squamous cell carcinoma skin , superficial transitional cell carcinoma bladder eligible ; Any uncontrolled know active infection , include chronic active hepatitis B , hepatitis C , HIV . Testing mandatory unless clinically indicate . Participants know Hepatitis B/C infection allow participate provide evidence viral suppression document patient remain appropriate antiviral therapy ; Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption capecitabine/temozolomide ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome substantial small bowel resection ) ; Presence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule , include alcohol dependence drug abuse ; Pregnancy , lactation , inadequate contraception . Women must postmenopausal , infertile , use reliable mean contraception . Women childbearing potential must negative pregnancy test do within 7 day prior registration . Men must surgically sterilise use ( double require ) barrier method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>midgut</keyword>
	<keyword>pancreatic</keyword>
	<keyword>neuroendocrine</keyword>
	<keyword>advanced</keyword>
	<keyword>unresectable low</keyword>
	<keyword>intermediate grade</keyword>
	<keyword>mNETs</keyword>
	<keyword>pNETs</keyword>
</DOC>